文献速递胸部肿瘤放疗放疗物理与技术

局部晚期肺癌左前降支冠状动脉保护性放疗的可行性

Feasibility of Left Anterior Descending Coronary Artery Sparing Radiation Therapy for Locally Advanced Lung Cancer.
PubMed 文献 · Pract Radiat Oncol · 2024-07-04

单中心回顾性分析54例2018年2月至2021年8月接受胸部放疗的局部晚期肺癌患者,对21例左前降支(LAD)V15Gy≥10%的计划行LAD再优化,结果显示LAD平均V15Gy和平均剂量显著降低,且85.7%再优化计划达到LAD V15Gy<10%。

要点

  • 在21例LAD V15Gy≥10%的局部晚期肺癌IMRT/VMAT计划中,再优化使LAD平均V15Gy从39.4%降至9.4%(P<.001)。
  • 85.7%(18/21)再优化计划达到LAD V15Gy<10%,仅1例超出原计划已满足的危及器官约束。
  • 全肺、食管和脊髓剂量指标无统计学显著差异,支持将LAD作为危及器官常规纳入现代胸部IMRT/VMAT计划。

核心结论

  • LAD V15Gy<10%在超过85%的初始超限计划中可实现,且剂量学代价极小,支持将LAD作为危及器官常规纳入现代胸部IMRT/VMAT计划。

研究设计与样本

  • 单中心回顾性分析,纳入2018年2月至2021年8月接受胸部放疗的54例局部晚期肺癌患者。
  • 排除33例(5例非IMRT/VMAT或有意LAD优化;28例LAD V15Gy<10%),对21例LAD V15Gy≥10%的计划行LAD再优化。
  • 再优化目标为LAD V15Gy<10%,同时维持原计划参数的危及器官指标和靶区覆盖;剂量学变量采用配对t检验比较。

主要发现

  • 再优化计划较原计划显著降低平均LAD V15Gy(39.4%±13.9% vs 9.4%±13.0%;P<.001)。
  • 再优化计划较原计划显著降低平均LAD剂量(12.9 Gy±4.6 Gy vs 7.6 Gy±2.8 Gy;P<.001)。
  • 85.7%(18/21)再优化计划达到LAD V15Gy<10%。
  • 全肺、食管和脊髓剂量指标无统计学显著差异;仅1例(1/21)再优化超出原计划已满足的危及器官约束。
  • 21例中57.1%(12/21)接受根治性放疗,38.1%(8/21)接受术后放疗,1例接受新辅助放疗;中位处方剂量60 Gy(范围50.4-66 Gy),30次(范围28-33次)。

关键数值与推荐

  • LAD V15Gy≥10%为再优化筛选阈值,再优化目标为LAD V15Gy<10%。
  • 再优化后平均LAD V15Gy为9.4%±13.0%,平均LAD剂量为7.6 Gy±2.8 Gy。

临床怎么用

  • 作者认为结果支持将LAD作为危及器官常规纳入现代胸部IMRT/VMAT计划。
  • 对LAD V15Gy≥10%的局部晚期肺癌计划可行LAD再优化,以LAD V15Gy<10%为目标并维持危及器官约束和靶区覆盖。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Efforts to mitigate radiation therapy (RT)-associated cardiotoxicity have focused on constraining mean heart dose. However, recent studies have shown greater predictive power with cardiac substructure dose metrics, such as the left anterior descending (LAD) coronary artery volume (V) receiving 15 Gy (V15Gy) ≥10%. Herein, we investigated the feasibility of LAD radiation sparing in contemporary intensity modulated RT (IMRT)/volumetric modulated arc therapy (VMAT) lung cancer plans. Single institution retrospective analysis of 54 patients with locally advanced lung cancer treated with thoracic RT was conducted between February 2018 and August 2021. After excluding 33 (5 = non-IMRT/VMAT or intentionally LAD-optimized; 28 = LAD V15Gy <10%), 21 plans with LAD V15Gy ≥10% were identified for LAD reoptimization with intent to meet LAD V15Gy <10% while maintaining meeting organ at risk (OAR) metrics and target coverage with original plan parameters. Dosimetric variables were compared using paired t tests. Most patients (57.1%, 12/21) were treated with definitive RT, 8 of 21 patients (38.1%) with postoperative RT, and 1 with neoadjuvant RT. The median prescribed RT dose was 60 Gy (range, 50.4-66 Gy) in 30 fractions (range, 28-33 fractions). LAD reoptimized plans (vs original) led to significant reductions in mean LAD V15Gy (39.4% ± 13.9% vs 9.4% ± 13.0%; P < .001) and mean LAD dose (12.9 Gy ± 4.6 Gy vs 7.6 Gy ± 2.8 Gy; P < .001). Most (85.7%; 18/21) LAD reoptimized plans achieved LAD V15Gy <10%. There were no statistically significant differences in overall lung, esophageal, or spinal cord dose metrics. Only 1 reoptimization (1/21) exceeded an OAR constraint that was initially met in the original plan. To our knowledge, this is the first report describing the feasibility of LAD-optimized lung cancer RT planning using the newly identified LAD V15Gy constraint. We observed that LAD V15Gy <10% is achievable in more than 85% of plans initially exceeding this constraint, with minimal dosimetric tradeoffs. Our results support the feasibility of routine incorporation of the LAD as an OAR in modern thoracic IMRT/VMAT planning.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang SC, Silos KD, Gasho JO, et al. Feasibility of Left Anterior Descending Coronary Artery Sparing Radiation Therapy for Locally Advanced Lung Cancer. Pract Radiat Oncol. 2024. PMID: 38971219. doi:10.1016/j.prro.2024.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。